Use of succinate as biomarker in diagnosis and treatment of cancers

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KUO, CHENGIN, WU, JING-YIING
Format: Patent
Sprache:chi ; eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator KUO, CHENGIN
WU, JING-YIING
description The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provide
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_TWI756870BB</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>TWI756870BB</sourcerecordid><originalsourceid>FETCH-epo_espacenet_TWI756870BB3</originalsourceid><addsrcrecordid>eNqNyzEKwkAQRuFtLES9w1xAEERjnaBoH7EM4-SPDJrZsDPeXwQPYPWa781Tc3VQHsjfImocIHa6ax65PFFIjXrlh2VXJ7aeooBjhMV3EjZB8WWaDfxyrH5dJDod2-a8xpQ7-MQCQ3Tt7VLt9odqU9fbP8gH9E4yOg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Use of succinate as biomarker in diagnosis and treatment of cancers</title><source>esp@cenet</source><creator>KUO, CHENGIN ; WU, JING-YIING</creator><creatorcontrib>KUO, CHENGIN ; WU, JING-YIING</creatorcontrib><description>The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provide</description><language>chi ; eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220301&amp;DB=EPODOC&amp;CC=TW&amp;NR=I756870B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220301&amp;DB=EPODOC&amp;CC=TW&amp;NR=I756870B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KUO, CHENGIN</creatorcontrib><creatorcontrib>WU, JING-YIING</creatorcontrib><title>Use of succinate as biomarker in diagnosis and treatment of cancers</title><description>The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provide</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyzEKwkAQRuFtLES9w1xAEERjnaBoH7EM4-SPDJrZsDPeXwQPYPWa781Tc3VQHsjfImocIHa6ax65PFFIjXrlh2VXJ7aeooBjhMV3EjZB8WWaDfxyrH5dJDod2-a8xpQ7-MQCQ3Tt7VLt9odqU9fbP8gH9E4yOg</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>KUO, CHENGIN</creator><creator>WU, JING-YIING</creator><scope>EVB</scope></search><sort><creationdate>20220301</creationdate><title>Use of succinate as biomarker in diagnosis and treatment of cancers</title><author>KUO, CHENGIN ; WU, JING-YIING</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_TWI756870BB3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>KUO, CHENGIN</creatorcontrib><creatorcontrib>WU, JING-YIING</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KUO, CHENGIN</au><au>WU, JING-YIING</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Use of succinate as biomarker in diagnosis and treatment of cancers</title><date>2022-03-01</date><risdate>2022</risdate><abstract>The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provide</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_TWI756870BB
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Use of succinate as biomarker in diagnosis and treatment of cancers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T06%3A05%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KUO,%20CHENGIN&rft.date=2022-03-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ETWI756870BB%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true